Hubei Guangji Pharmaceutical Co., Ltd.

Sümbol: 000952.SZ

SHZ

6.12

CNY

Turuhind täna

-14.2334
P/E suhe
-0.0163
PEG suhe
2.10B
MRK Cap
0.00%
DIV tootlus

Hubei Guangji Pharmaceutical Co., Ltd. (000952-SZ) Finantsaruanded

Q: Mis on ettevõtte kasumimarginaal?

Ettevõtte kasumimarginaal on .

Download

Aastane Quarterly

Lineaarne Log

Diagrammil näete Hubei Guangji Pharmaceutical Co., Ltd. (000952.SZ) vaikimisi numbreid dünaamikates. Companys revenue näitab keskmist 470.101 M, mis on 0.079 % gowth. Kogu perioodi keskmine brutokasum on 170.696 M, mis on 0.215 %. Keskmine brutokasumi suhtarv on 0.353 %. Ettevõtte eelmise aasta tulemuse puhaskasv on -3.786 %, mis on võrdne -2.383 % % keskmiselt kogu ettevõtte ajaloo jooksul.,

Aastane Quarterly

10Y 20Y 30Y 40Y

Bilanss

Sukeldudes Hubei Guangji Pharmaceutical Co., Ltd. fiskaalkäiguteele, täheldame keskmist varade kasvu. See määr on huvitaval kombel , mis kajastab nii ettevõtte kõrg- kui ka madalseisusid. Kui võrrelda kvartalite lõikes, siis kohandub see näitaja 0. Kui vaadata tagasi möödunud aastale, siis on varade kogumuutus 0.227. Käibevara valdkonnas on 000952.SZ aruandlusvaluutas 1084.666. Märkimisväärne osa neist varadest, täpsemalt 415.244, hoitakse sularahas ja lühiajalistes investeeringutes. See segment näitab eelmise aasta andmetega võrreldes muutust -0.037%. Ettevõtte pikaajalised investeeringud, kuigi need ei ole tema fookuses, seisavad 45.355, kui neid on, aruandlusvaluutas. See näitab erinevust 2.773% võrreldes eelmise aruandeperioodiga, mis kajastab ettevõtte strateegilisi muutusi. Ettevõtte võlaprofiil näitab, et ettevõtte pikaajaline koguvõlg on 419.537 aruandlusvaluutas. See näitaja tähendab, et aastane muutus on 0.546%. Aktsionäride väärtus, mida näitab aktsionäride kogu omakapital, on hinnatud 1363.446 aruandlusvaluutas. Selle aspekti aastane muutus on -0.093%. Kui süveneda ettevõtte finantsnäitajatesse, ilmneb täiendavaid üksikasju. Netovõlad on hinnatud 350.696, varude hind on 298.99 ja firmaväärtus 0, kui see on olemas. Kogu immateriaalne vara, kui see on olemas, hinnatakse 216.91. Kontovõlad ja lühiajalised võlad on vastavalt 143.02 ja 516.32. Koguvõlg on 935.86, netovõlg on 520.62. Muud lühiajalised kohustused moodustavad 90.93, mis lisandub kohustuste kogusummale 1637.07. Lõpuks hinnatakse viidatud aktsia 0.01, kui see on olemas.

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014	2012	2010	2008	2006	2004	2002	2000	1998	1996
balance-sheet.row.cash-and-short-term-investments	2401.91	415.2	431.4	293.3	350.3	183.7	173.6	140.8	116.7	161.9	194.8	111	125	152.3	211.8	188.8	220.1	172.2	72.6	32.1	45.7	69.1	135.8	95.5	117.1	113.2	6.9	2.9	2.8
balance-sheet.row.short-term-investments	-21.47	-10.2	0	0	-0.1	-0.4	-0.5	-0.5	0	0	0	0	0	0	0	0	0	0.3	10.5	10	10	11	0	0	25	30	0	0	0
balance-sheet.row.net-receivables	1407.13	350.7	339.9	238.5	169.6	172.3	177.4	161.7	167.1	139.4	76.7	231.9	134	149	180.3	245.2	257.7	202.5	209.8	381.2	389.2	390.7	201.8	205.1	41.2	24.9	17.5	4.7	8.1
balance-sheet.row.inventory	1249.74	299	221.5	164.8	163.6	137.9	98.5	98.4	109.2	98.9	151.5	170.8	181.9	203.7	97.6	52.4	91.4	60.7	50.9	60	62.4	61.8	59.9	59.6	48.8	55.6	84.5	78	41.6
balance-sheet.row.other-current-assets	68.42	19.7	12.7	12.3	18.6	20.4	19.1	19.7	23.2	32.6	55	-63	-25.1	-24.1	-32.9	-46.5	-43.3	0.7	-44.3	-106.8	-108	-125.5	2	9.4	127.8	138.7	126.8	100.6	56.9
balance-sheet.row.total-current-assets	5127.21	1084.7	1005.5	709	702.1	514.3	468.6	420.5	416.3	432.8	477.9	450.8	415.8	481	456.8	439.9	526	436	288.9	366.5	389.3	396	399.4	369.6	334.9	332.5	235.6	186.3	109.3
balance-sheet.row.property-plant-equipment-net	5756.25	1637.1	1199.2	1069.2	1041.9	963.4	959.5	969.3	974.5	942.5	854.6	858.4	863.8	865.8	780.5	684.9	502.9	376.5	336.8	353.2	352.5	325.4	277.5	256.6	218.8	223.3	107	108.3	96.7
balance-sheet.row.goodwill	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.intangible-assets	728.73	216.9	150.6	154.7	161.6	168.5	165.5	169.3	183	191.8	193.5	196.9	190.9	75	62.6	65	83.9	53.7	38.6	41.9	45.5	49.8	53.2	47.3	37.5	36.6	34.3	36.5	37
balance-sheet.row.goodwill-and-intangible-assets	728.73	216.9	150.6	154.7	161.6	168.5	165.5	169.3	183	191.8	193.5	196.9	190.9	75	62.6	65	83.9	53.7	38.6	41.9	45.5	49.8	53.2	47.3	37.5	36.6	34.3	36.5	37
balance-sheet.row.long-term-investments	167.19	45.4	44.1	39.8	22.8	27.8	32.1	34.5	0	0	0	0	0	77.9	0	0	0	107.3	108.2	108.1	109.1	78.3	0	0	58.8	23.6	0	0	0
balance-sheet.row.tax-assets	90.73	15.9	26.8	24.8	21.8	17.6	18.6	21.5	0	0	0	6.5	5.1	6.9	6.2	7.6	12.5	25	11.9	12.2	12.9	14.7	0	0	25.5	32	0	0	0
balance-sheet.row.other-non-current-assets	596	29.6	42.8	51.4	29.4	74.9	49	26.7	60.1	53.6	56.4	39.2	80.4	0	78.4	106.4	81.8	0.3	0.6	0.6	2.6	2.6	89.7	88.3	0.7	0.8	1.8	2	1.9
balance-sheet.row.total-non-current-assets	7338.9	1944.9	1463.6	1339.9	1277.4	1252.2	1224.7	1221.4	1217.6	1187.9	1104.5	1101	1140.2	1025.7	927.6	864	681.1	562.8	496.1	516	522.7	470.9	420.5	392.2	341.3	316.3	143.1	146.8	135.6
balance-sheet.row.other-assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-assets	12466.11	3029.5	2469.1	2048.9	1979.4	1766.5	1693.3	1641.9	1633.9	1620.7	1582.5	1551.8	1556	1506.7	1384.4	1303.8	1207.1	998.8	785	882.4	912	866.9	819.9	761.8	676.2	648.8	378.8	333	244.9
balance-sheet.row.account-payables	542.15	143	178.6	121.6	139.1	104.4	103.2	118.5	162.8	254.2	290.6	332.4	307.4	161.5	96.1	98.5	90.1	54.6	51.8	40	66	62.3	59.1	50.6	42.2	18.9	22.3	39.3	4.4
balance-sheet.row.short-term-debt	2189.84	516.3	357.2	336.7	219.4	521.7	524.4	531.4	506.9	207.7	189	202.2	251.5	264	207.1	135	81	68	135	192	208.2	178.2	175.2	149.8	45.4	79.4	125.4	62	46.5
balance-sheet.row.tax-payables	43.64	12.1	17.6	13.6	18.6	7.2	14.2	29.8	17.6	9	13.6	-28.6	-34	-30.9	-16.7	-5.7	96.4	112	-3.3	-5.5	-7.8	-4.3	-7	-0.9	7.6	9.5	3.4	0.3	-0.3
balance-sheet.row.long-term-debt-total	1740.97	419.5	248.1	36.1	84.4	74.8	27.5	80.5	132.6	308	317	79.5	124.6	103.5	121.8	142.7	0	10	77.5	72	83.2	73	50	40	69	48	7.1	38	36.5
Deferred Revenue Non Current	63.79	15.7	18.1	21	23.3	25.8	27.5	31.3	34.4	43.6	49.7	47.9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.deferred-tax-liabilities-non-current	751.08	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
balance-sheet.row.other-current-liab	305.05	90.9	112.7	0.9	2.6	5.7	86.2	20.9	28.8	15.8	31.1	15.3	14.6	8.8	11.4	11.6	7.8	13.7	15.3	14.5	11.6	14.5	15.4	9.6	5.6	2.8	0.1	6.3	0.1
balance-sheet.row.total-non-current-liabilities	3276.47	771.2	323.2	57.8	153.3	100.6	84.3	113.9	179.7	545.8	383.1	127.5	158.8	122.6	140.5	158.2	16.8	10	77.5	79.1	84.1	73.5	50.1	40.1	69.1	51.1	10.8	41.1	39.2
balance-sheet.row.other-liabilities	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.capital-lease-obligations	9.86	2.2	3.2	1.6	0	27	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-liab	6780.93	1637.1	977.2	598.1	613.7	802.2	812.3	876.6	974.7	1106.9	1077	816.8	795.9	643.1	545.1	486.9	395.8	325.8	307.3	350.7	388.8	352.4	313	275	194.7	199.5	186.8	166.8	110.7
balance-sheet.row.preferred-stock	0.01	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.common-stock	1415.67	353.9	354	344	347	251.7	251.7	251.7	251.7	251.7	251.7	251.7	251.7	251.7	251.7	251.7	251.7	251.7	251.7	171.2	171.2	171.2	171.2	171.2	171.2	171.2	121.2	121.2	86.6
balance-sheet.row.retained-earnings	2151.24	502.7	644.6	626.9	554.4	584.9	505.8	368.4	265.7	123.9	102.9	321.7	319.3	414.8	412.3	401.7	363.1	308.4	139.3	125.3	118	111	104.4	87.6	84.3	56.8	44.7	22.8	30.2
balance-sheet.row.accumulated-other-comprehensive-income-loss	754.23	0	158.5	172.2	155.4	127.6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.other-total-stockholders-equity	1286.99	506.9	345.6	319.3	316.4	-3.8	115.7	139.2	136.6	136.6	143.5	143.5	148	149.5	142.4	139.1	133.4	107.1	86.2	234.9	233.6	232.3	231.2	228.1	226	221.3	26	22.2	17.4
balance-sheet.row.total-stockholders-equity	5608.14	1363.4	1502.6	1462.5	1373.1	960.4	873.3	759.2	654	512.2	498.2	716.9	718.9	816	806.5	792.5	748.3	667.2	477.3	531.3	522.8	514.6	506.9	486.9	481.5	449.3	192	166.2	134.2
balance-sheet.row.total-liabilities-and-stockholders-equity	12466.11	3029.5	2469.1	2048.9	1979.4	1766.5	1693.3	1641.9	1633.9	1620.7	1582.5	1551.8	1556	1506.7	1384.4	1303.8	1207.1	998.8	785	882.4	912	866.9	819.9	761.8	676.2	648.8	378.8	333	244.9
balance-sheet.row.minority-interest	77.05	29	-10.8	-11.7	-7.4	3.9	7.7	6	5.2	1.7	7.3	18.1	41.1	47.6	32.9	24.4	63	5.8	0.4	0.4	0.4	0	0	0	0	0	0	0	0
balance-sheet.row.total-equity	5685.19	1392.4	1491.8	1450.8	1365.7	964.3	881	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
balance-sheet.row.total-liabilities-and-total-equity	12466.11	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Investments	145.72	35.2	44.1	39.8	22.6	27.4	31.6	34	35.5	38.9	39.4	39	80.4	78	78.4	106.4	81.8	107.6	118.7	118.1	119.1	89.3	87	87.4	83.8	53.6	0	0	0
balance-sheet.row.total-debt	3930.81	935.9	605.4	372.8	303.8	596.5	551.9	531.4	506.9	515.7	506	281.7	376.1	367.5	329	277.7	81	78	212.5	264	291.4	251.2	225.2	189.8	114.4	127.4	132.5	100	82.9
balance-sheet.row.net-debt	1528.9	520.6	174	79.5	-46.5	412.8	378.4	390.5	390.2	353.8	311.2	170.7	251.1	215.2	117.2	88.9	-139.1	-94.2	150.4	241.9	255.7	193.1	89.4	94.3	22.3	44.2	125.7	97	80.1

Rahavoogude aruanne

Hubei Guangji Pharmaceutical Co., Ltd. finantsmaastikul on viimase perioodi jooksul toimunud märkimisväärne muutus vabas rahavoos, mis näitab -3.508 nihet. Ettevõte laiendas hiljuti oma aktsiakapitali, emiteerides 0, mis tähistab -0.032 erinevust võrreldes eelmise aastaga. Huvitav on see, et osa ettevõtte aktsiatest, täpsemalt 0, ostis ettevõte ise tagasi. Selle tegevuse tulemusena muutus 0.000 võrreldes eelmise aastaga. Vahepeal on ettevõtte võlgnevused praegu 29.87 aruandlusvaluutas. Ettevõtte investeerimistegevuse tulemusel kasutas ettevõte netosularaha, mis aruandlusvaluutas oli -121737831.980. See on 0.067 nihkumine võrreldes eelmise aastaga. Samal perioodil registreeris ettevõte 98.31, -3.49, -415.44, mis on olulised ettevõtte investeerimis-ja tagasimaksestrateegiate mõistmiseks. Ettevõtte finantseerimistegevuse tulemusel kasutas ettevõte netorahavahendeid 0.000, kusjuures erinevus võrreldes eelmise aastaga oli 0.000. Lisaks eraldas ettevõte -40.24 aktsionäridele dividendide maksmiseks. Samal ajal tegi ta muid finantsmanöövreid, millele viidatakse kui 756.62, mis samuti mõjutasid oluliselt tema rahavooge sel perioodil. Need komponendid koos annavad tervikliku pildi ettevõtte finantsseisundist ja strateegilisest lähenemisest rahavoogude juhtimisele.

common:word.in-mln USD Growth	TTM	2021	2019	2017	2015	2013	2011	2009	2007	2005	2003	2001	1999
cash-flows.row.net-income	-146.72	47.7	105.8	70.3	83.2	173.4	106.1	145.3	18.4	-229.6	-5	-103.5	0.8	9.4	37.2	97.3	195.6	15.7	8.6	8.1	7.7	19.9	24.6	30.6	31.4	25.7
cash-flows.row.depreciation-and-amortization	94.63	98.3	91.3	90.4	81.3	82.8	82.5	73.1	54.4	68.2	66.9	62.2	58.8	52.8	37.9	34.2	30.4	30.8	28.1	23.9	22.5	19.3	20.3	12.2	14	11.9
cash-flows.row.deferred-income-tax	-0.1	-2.3	-2.7	-4.1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.stock-based-compensation	7.28	9.5	2.7	4.1	-1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.change-in-working-capital	-152.33	-138.8	-121.4	-50.9	-61.9	-63.2	-78.5	-99.1	-171.8	-24.1	32.4	115.4	-1.6	1.9	-85.6	67.1	50.1	44.3	-4.8	-50.4	-64.8	24.4	-87.4	6.3	9.8	-53.6
cash-flows.row.account-receivables	-53.06	-102.1	-66.9	475.9	2.6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.inventory	-100.18	-64.3	-4.3	-26.8	-43	3.1	10.9	-11.5	48.2	-5.5	10.5	23.4	-109.4	-46.7	38	-30.7	0.4	9.2	0.9	-0.6	-1.9	-0.5	10.8	6.4	28.2	-6.5
cash-flows.row.account-payables	0	29.9	-47.4	-495.7	-22.6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.other-working-capital	0.91	-2.3	-2.7	-4.1	1	-66.4	-89.3	-87.6	-220	-18.6	21.9	92	107.7	48.6	-123.6	97.8	49.7	35.1	-5.7	-49.8	-62.9	24.9	-98.2	-0.1	-18.4	-47.1
cash-flows.row.other-non-cash-items	70.34	30.7	0.2	9.5	41.7	38.4	68.7	47.8	65.6	110.8	0.9	33.9	23.9	13.1	-13.8	22	55.8	35.2	22.3	15	19.2	12.6	20.1	-0.5	13.3	0.6
cash-flows.row.net-cash-provided-by-operating-activities	-134.19	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.investments-in-property-plant-an-equipment	-559.78	-203.7	-96.6	-97.9	-119.8	-76.5	-80.9	-112.9	-109.9	-94.6	-50	-117.5	-201	-115.6	-149.9	-219.8	-48.9	-18.7	-25.8	-47.6	-65.7	-50.5	-46.8	-25.1	-135.6	-3
cash-flows.row.acquisitions-net	52	3.5	0.7	41.4	0.1	0	0	0	110	1.2	59.8	117.7	12.4	13	13.3	0.1	-1.2	0	26	47.6	66.1	0	0	25.6	0	0
cash-flows.row.purchases-of-investments	0	-10	-80	-830	-0.1	0	0	0	-10	-34	-2	-8	-7	-8	-67.6	-15	-29.6	-2.3	-0.9	-13	-20.4	-2	-9	-21.6	-83.6	0
cash-flows.row.sales-maturities-of-investments	-74	92	61.8	773.5	0.1	0.2	0.2	2.5	0.3	38.4	37.5	7.1	8	12.3	10.4	10	1.5	0	1.9	13	10	0	26	8	0	0
cash-flows.row.other-investing-activites	0.35	-3.5	0	0.2	0.1	0.1	1	1.4	-109.9	10	-50	-117.5	16.3	2.5	0.5	56	0.4	0.1	-25.8	-47.6	-65.7	0.6	10	-25.1	0.5	0
cash-flows.row.net-cash-used-for-investing-activites	-559.42	-121.7	-114.1	-112.8	-119.5	-76.2	-79.7	-109.1	-119.6	-79	-4.8	-118.1	-171.3	-95.7	-193.3	-168.7	-77.8	-21	-24.7	-47.5	-75.8	-51.9	-19.8	-38.2	-218.6	-3
cash-flows.row.debt-repayment	-344	-415.4	-399.5	-680.1	-563.9	-495.7	-476	-148	-272.7	-357.1	-355.8	-356.2	-326.5	-177.7	-150	-102	-226.5	-205.3	-168.2	-154.7	-190.2	-37.9	-47.4	-51.1	-53.1	-21.7
cash-flows.row.common-stock-issued	0	0	0	-5.9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.common-stock-repurchased	0	0	0	5.9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.dividends-paid	-36.9	-40.2	-35.7	-49.5	-29.3	-50.9	-31.8	-35.5	-36.1	-21.2	-26.4	-25.8	-21.1	-12.8	-6.2	-26.7	-10.4	-13.5	-15.7	-11.8	-12.5	-19.4	-9.6	-13.1	-12.5	-10.9
cash-flows.row.other-financing-activites	931.87	756.6	388.4	832.7	576.5	424.2	440	87.7	423.7	619.6	261.4	364.8	377.5	232	342.6	124.7	92	153.8	140.8	194.9	216.2	73.3	102.6	62.7	292.1	54.8
cash-flows.row.net-cash-used-provided-by-financing-activities	707.19	300.9	-46.8	103.1	-16.8	-122.4	-67.8	-95.9	114.9	241.2	-120.8	-17.2	29.9	41.5	186.4	-4.1	-144.9	-65	-43.1	28.4	13.5	16	45.6	-1.5	226.4	22.2
cash-flows.row.effect-of-forex-changes-on-cash	0.78	1.4	-1.5	-3.8	2.2	-0.1	2.8	0.1	0.2	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0
cash-flows.row.net-change-in-cash	14.36	225.7	-86.5	105.9	10.1	32.7	34.2	-37.7	-37.8	87.5	-30.4	-27.3	-59.4	22.9	-31.3	47.9	109.3	40	-13.5	-22.4	-77.7	40.3	3.4	8.9	76.4	4
cash-flows.row.cash-at-end-of-period	2397.91	428.8	203.1	289.5	183.7	173.6	140.8	106.7	144.4	182.2	94.6	125	152.3	211.8	188.8	220.1	172.2	62.1	22.1	35.7	58.1	135.8	95.5	92.1	83.2	6.9
cash-flows.row.cash-at-beginning-of-period	2383.56	203.1	289.5	183.7	173.6	140.8	106.7	144.4	182.2	94.6	125	152.3	211.8	188.8	220.1	172.2	62.9	22.1	35.7	58.1	135.8	95.5	92.1	83.2	6.9	2.9
cash-flows.row.operating-cash-flow	-134.19	45.1	75.9	119.4	144.2	231.4	178.8	167.1	-33.3	-74.7	95.2	108	81.9	77.2	-24.3	220.7	332	126	54.1	-3.3	-15.4	76.2	-22.4	48.6	68.6	-15.3
cash-flows.row.capital-expenditure	-559.78	-203.7	-96.6	-97.9	-119.8	-76.5	-80.9	-112.9	-109.9	-94.6	-50	-117.5	-201	-115.6	-149.9	-219.8	-48.9	-18.7	-25.8	-47.6	-65.7	-50.5	-46.8	-25.1	-135.6	-3
cash-flows.row.free-cash-flow	-693.96	-158.6	-20.7	21.5	24.4	154.9	97.9	54.1	-143.3	-169.3	45.1	-9.4	-119.1	-38.4	-174.3	0.9	283	107.2	28.3	-50.9	-81.1	25.7	-69.2	23.5	-67	-18.2

Kasumiaruande rida

Hubei Guangji Pharmaceutical Co., Ltd. tulud muutusid võrreldes eelmise perioodiga -0.075%. 000952.SZ brutokasum on teatatud 202.2. Ettevõtte tegevuskulud on 275.42, mille muutus võrreldes eelmise aastaga on 31.791%. Kulud amortisatsioonikulud on 98.31, mis on 0.220% muutus võrreldes eelmise aruandeperioodiga. Tegevuskulud on teatatud 275.42, mis näitab 31.791% muutust võrreldes eelmise aastaga. Müügi- ja turunduskulud on 0, mis on 0.000% muutus võrreldes eelmise aastaga. Hiljutistel numbritel põhinev EBITDA on 0, mis tähendab -2.445% kasvu võrreldes eelmise aastaga. Tegevustulu on -141.05, mis näitab -2.445% muutust võrreldes eelmise aastaga. Puhaskasumi muutus on -3.786%. Eelmise aasta puhaskasum oli -140.25.

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014	2012	2010	2008	2006	2004	2002	2000	1998	1996
income-statement-row.row.total-revenue	802.69	737.8	797.6	837.1	688.2	731.3	843.8	801.6	714.7	560.4	485.9	487.1	394.2	453.3	483.3	448.2	571.8	794.9	388.7	345.8	276.6	204.1	202.2	186.1	134.1	176.6	161.3	141.2	114.9
income-statement-row.row.cost-of-revenue	592.07	535.6	502.5	535.9	408.5	391.5	364.4	393.6	341.7	379.3	440.5	427.2	380.6	359.4	388.6	353.9	341.2	337.9	271.5	260.9	209.1	130.8	127.3	105.5	68.8	98.2	89.3	71.1	68.6
income-statement-row.row.gross-profit	210.62	202.2	295.1	301.2	279.6	339.8	479.5	407.9	373	181.1	45.3	59.9	13.6	93.9	94.7	94.3	230.6	457	117.2	85	67.5	73.3	74.9	80.6	65.4	78.4	72	70.2	46.3
income-statement-row.row.gross-profit-ratio	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
income-statement-row.row.research-development	74.42	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-general-administrative	93.38	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-and-marketing-expenses	39.31	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-expenses	1.89	0.4	62	57.5	53.8	42.3	-4.1	-13.7	-1.3	17	5.6	51.6	17.3	7.1	11.5	2.8	3.2	0.8	-8.4	-2	-0.5	0.2	0	-0.2	-0.1	9.8	-0.3	0.1	0.1
income-statement-row.row.operating-expenses	290.39	275.4	209	185.4	172.6	203.3	228	198	171	116.7	155.9	107.8	94.6	75.5	76	68.9	99.8	125.1	69.7	49	40.9	41	36.6	31.9	25.6	32.1	30.3	23.9	18.9
income-statement-row.row.cost-and-expenses	882.46	811	711.5	721.2	581.2	594.8	592.3	591.6	512.7	496	596.4	535	475.2	434.9	464.6	422.7	441	463	341.2	309.9	250	171.8	163.9	137.4	94.4	130.3	119.6	95	87.5
income-statement-row.row.interest-income	3.4	3.5	2	3.2	1.4	1.1	0.6	0.7	1.3	2.6	2.6	2.2	1.2	5.5	1.2	0	2.8	1.1	0.3	0.3	0.3	0.4	1.2	0.8	0.8	0	0	0	0
income-statement-row.row.interest-expense	52.95	49.2	21.1	16.7	32.6	35.1	30.7	33.7	36.3	35.8	25	28.8	24.9	21.1	12.8	4.6	5	10.9	13.5	15.9	11.8	11.7	11.5	9.2	5.8	12.1	10.9	11.3	8.3
income-statement-row.row.selling-and-marketing-expenses	39.31	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.total-other-income-expensenet	1.89	0.4	-37.5	6.1	-8.7	-37.1	-44.5	-88.4	-46.4	-46	-112.5	41.5	-21	-14.2	-3.1	18.1	-13.3	-49.3	-21.9	-19.7	-13.9	-14.2	-10.9	-16.6	-3.1	-2.3	-11.3	-11.2	-8.8
income-statement-row.row.ebitda-ratio-caps	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-operating-expenses	1.89	0.4	62	57.5	53.8	42.3	-4.1	-13.7	-1.3	17	5.6	51.6	17.3	7.1	11.5	2.8	3.2	0.8	-8.4	-2	-0.5	0.2	0	-0.2	-0.1	9.8	-0.3	0.1	0.1
income-statement-row.row.total-operating-expenses	1.89	0.4	-37.5	6.1	-8.7	-37.1	-44.5	-88.4	-46.4	-46	-112.5	41.5	-21	-14.2	-3.1	18.1	-13.3	-49.3	-21.9	-19.7	-13.9	-14.2	-10.9	-16.6	-3.1	-2.3	-11.3	-11.2	-8.8
income-statement-row.row.interest-expense	52.95	49.2	21.1	16.7	32.6	35.1	30.7	33.7	36.3	35.8	25	28.8	24.9	21.1	12.8	4.6	5	10.9	13.5	15.9	11.8	11.7	11.5	9.2	5.8	12.1	10.9	11.3	8.3
income-statement-row.row.depreciation-and-amortization	72.09	120	98.3	114.7	119.6	81.3	82.8	82.5	73.1	54.4	68.2	66.9	62.2	58.8	52.8	37.9	34.2	30.4	30.8	28.1	23.9	22.5	19.3	20.3	12.2	14	11.9	10.6	7.9
income-statement-row.row.ebitda-caps	-79.85	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.operating-income	-151.94	-141.1	97.6	118.2	96.8	137	211.1	135.3	159.2	21.9	-226.5	-58.1	-118.7	-2.8	5.3	40.8	114.3	281.7	33.8	18.2	13.2	17.9	27.3	32.3	37	34.2	30.8	35.6	19.5
income-statement-row.row.income-before-tax	-150.05	-140.7	60.1	124.3	88.1	99.9	207.1	121.6	155.6	18.4	-223.1	-6.4	-102	4.2	15.6	43.6	117.5	282.6	25.5	16.2	12.7	18.1	27.3	32.1	36.8	44	30.4	35.4	19.1
income-statement-row.row.income-tax-expense	11.63	11.7	12.4	18.5	17.8	16.7	33.7	15.5	10.3	0	6.5	-1.5	1.6	3.4	6.2	6.4	29.9	99.8	9.8	7.7	4.5	10.4	7.4	7.5	6.1	12.6	4.7	3.3	1.7
income-statement-row.row.net-income	-146.72	-140.2	50.3	110.1	74.6	86.9	171.7	105.2	141.8	20.9	-218.7	2.4	-95.6	4.8	14	43	89.1	183.8	15.7	8.6	8.2	7.7	19.9	24.6	30.6	31.4	25.7	32	17.4